EZH2
Histone-lysine N-methyltransferase EZH2
As of the edition of 20 October 2026, EZH2 (histone-lysine N-methyltransferase EZH2, UniProt Q15910) has 9 drugs tested at it and 10 companies on the list, 3 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q15910
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 39
- Disease areas
- Cancer; Blood and lymph; Immune system; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Nervous system; Digestive system
- Registered trials of its drugs
- 108
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 5 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tazemetostat | Marketed | Phase 3 | Ends 2034 |
| SHR-2554 | Active | Phase 2 | none listed |
| Zeprumetostat | Active | Phase 2 | none listed |
| Mevrometostat | Active | Phase 3 | none listed |
| Tulmimetostat | Active | Phase 2 | none listed |
| XNW5004 | Active | Phase 2 | none listed |
| DS-3201b | Stopped | Phase 2 | none listed |
| CPI-1205 | Went quiet | Phase 2 | none listed |
| GSK2816126 | Stopped | Phase 1 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 2 |
| Engaged | 5 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| GSK | Route A |
| Ipsen | Route B |
| Daiichi Sankyo | Route A |
The other 7 companies at EZH2
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at EZH2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.